$2.07
0.0150.73%
Last update: Oct 27, 1:45 PM
Fate Therapeutics Inc (FATE) Stock Price, Quote, News & History
FATENASDAQ
Cathie Wood-led ARK Investment Management bought 21,050 shares of Tesla Inc (NASDAQ: TSLA) on Wednesday at an estimated valuation of over $2.39 million.
You can purchase shares of Fate Therapeutics (NASDAQ:FATE) through any online brokerage.
Other companies in Fate Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Fate Therapeutics has a consensus price target of $5.89.
The stock price for Fate Therapeutics (NASDAQ: FATE) is $2.07 last updated October 27, 2026 at 1:45 PM EDT.
There are no upcoming dividends for Fate Therapeutics.
Fate Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Fate Therapeutics.
Fate Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline...
